Spots Global Cancer Trial Database for hpv positive oropharyngeal squamous cell carcinoma
Every month we try and update this database with for hpv positive oropharyngeal squamous cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| De-escalation of Radiation Dose in HPV-associated OPC Utilising FMISO PET (DE-RADIATE) | NCT06307015 | HPV Positive Or... | De-escalation Standard of car... | 18 Years - | Royal North Shore Hospital | |
| De-escalation of Radiation Dose in HPV-associated OPC Utilising FMISO PET (DE-RADIATE) | NCT06307015 | HPV Positive Or... | De-escalation Standard of car... | 18 Years - | Royal North Shore Hospital | |
| Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma | NCT03215719 | Oropharyngeal C... HPV Positive Or... | Standard Radiat... Dose-Deescalate... Cisplatinum | 18 Years - | NYU Langone Health | |
| De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx | NCT05600842 | HPV Positive Or... | Intensity-Modul... | 18 Years - | University of California, Irvine | |
| Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer | NCT04444869 | Cancer of the H... Oropharynx Canc... HPV Positive Or... Throat Carcinom... | Cisplatin injec... | 18 Years - | University of Missouri-Columbia | |
| Interim Digital PET/CT in Predicting Outcomes for Participants With Locally Advanced Oropharyngeal Cancer Undergoing Chemoradiation Therapy | NCT03611205 | Oropharyngeal S... HPV Positive Or... | Computed Tomogr... Positron Emissi... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | NCT05686226 | Cervical Cancer Throat Cancer Oropharynx Canc... Anal Cancer Vulva Cancer Vaginal Cancer Penile Cancer Metastatic Canc... HPV-Related Mal... HPV-Related Car... HPV-Related Cer... HPV-Related Squ... HPV-Related Ade... HPV Positive Or... HPV-Associated ... HPV-Related Ade... HPV-Related End... HPV-Related Ana... HPV-Related Pen... HPV-Related Vul... HPV Positive Re... | E7 TCR-T cells | 18 Years - | Rutgers, The State University of New Jersey | |
| Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV | NCT04255849 | HPV Positive Or... HIV-1-infection HPV Infection | 9 valent human ... Saline Placebo | 20 Years - 50 Years | Weill Medical College of Cornell University | |
| A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC) | NCT05814549 | Oropharyngeal C... HPV-Related Car... HPV Positive Or... | NavDx | 45 Years - | Memorial Sloan Kettering Cancer Center | |
| Improving Detection and Early Action for HPV-positive Oropharynx Cancer | NCT04871490 | HPV Positive Or... | Blood test for ... | 35 Years - | Brigham and Women's Hospital | |
| A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC) | NCT05814549 | Oropharyngeal C... HPV-Related Car... HPV Positive Or... | NavDx | 45 Years - | Memorial Sloan Kettering Cancer Center | |
| Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer | NCT03601507 | CDKN2A-p16 Posi... HPV Positive Or... Stage I Orophar... Stage II Oropha... Stage III Oroph... Stage IVA Oroph... | Alpelisib Laboratory Biom... Pharmacodynamic... Therapeutic Con... | - | University of Arizona | |
| A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma | NCT03978689 | Head and Neck C... HPV Positive Or... HPV-Related Car... | CUE-101 KEYTRUDA® | 18 Years - | Cue Biopharma | |
| Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma | NCT05119036 | Squamous Cell C... HPV Positive Or... | 44 doses of rad... 54 doses of rad... | - | Indiana University | |
| TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers | NCT05108870 | Human Papilloma... HPV HPV Positive Or... Head and Neck C... | HB-201 HB-202 Carboplatin Paclitaxel Transoral Robot... | 18 Years - | University of Chicago | |
| A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma | NCT03978689 | Head and Neck C... HPV Positive Or... HPV-Related Car... | CUE-101 KEYTRUDA® | 18 Years - | Cue Biopharma | |
| Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients | NCT04001413 | HPV Positive Or... Oropharynx Canc... HPV-Related Car... | MEDI0457 Durvalumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| The SPOT-HPV Study | NCT05524025 | HPV Infection HPV Positive Or... | Salivary TTMV-H... Blood TTMV-HPV ... | 18 Years - | Dana-Farber Cancer Institute | |
| Improving Detection and Early Action for HPV-positive Oropharynx Cancer | NCT04871490 | HPV Positive Or... | Blood test for ... | 35 Years - | Brigham and Women's Hospital | |
| A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) | NCT05307939 | HPV Oropharynx Canc... HPV-Related Car... HPV-Related Mal... HPV Positive Or... | HPV ctDNA Assay MRI Studies EORTC QLQ H&N 3... MDADI-HN COST-FACIT Intensity-Modul... Chemoradiation ... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer | NCT04502407 | HPV Positive Or... | Cisplatin-based... Cisplatin Chemo... | 18 Years - | Cedars-Sinai Medical Center | |
| A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) | NCT05307939 | HPV Oropharynx Canc... HPV-Related Car... HPV-Related Mal... HPV Positive Or... | HPV ctDNA Assay MRI Studies EORTC QLQ H&N 3... MDADI-HN COST-FACIT Intensity-Modul... Chemoradiation ... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC | NCT04260126 | Metastatic Head... Recurrent Head ... HPV Positive Or... Neoplasms, Head... | Pembrolizumab (... | 18 Years - | PDS Biotechnology Corp. | |
| Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma | NCT05119036 | Squamous Cell C... HPV Positive Or... | 44 doses of rad... 54 doses of rad... | - | Indiana University | |
| The SPOT-HPV Study | NCT05524025 | HPV Infection HPV Positive Or... | Salivary TTMV-H... Blood TTMV-HPV ... | 18 Years - | Dana-Farber Cancer Institute | |
| Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV | NCT04255849 | HPV Positive Or... HIV-1-infection HPV Infection | 9 valent human ... Saline Placebo | 20 Years - 50 Years | Weill Medical College of Cornell University | |
| Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma | NCT01855451 | HPV Positive Or... | Cetuximab RT (70 Gy in 35... Cisplatin | 18 Years - | Trans Tasman Radiation Oncology Group | |
| Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors | NCT04301011 | Solid Tumor Microsatellite ... HPV Positive Or... Cervical Cancer Melanoma (Skin) Cutaneous Squam... Mesothelioma Renal Cell Carc... Oropharynx Canc... | TBio-6517 Pembrolizumab | 18 Years - | Turnstone Biologics, Corp. | |
| Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma | NCT01855451 | HPV Positive Or... | Cetuximab RT (70 Gy in 35... Cisplatin | 18 Years - | Trans Tasman Radiation Oncology Group | |
| Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck | NCT02113878 | Carcinoma, Squa... HPV Positive Or... Hypopharyngeal ... Early Invasive ... Carcinoma of La... Cancer of Nasop... | BKM120 Cisplatin Intensity-modul... | 18 Years - | Dana-Farber Cancer Institute | |
| De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx | NCT05600842 | HPV Positive Or... | Intensity-Modul... | 18 Years - | University of California, Irvine | |
| A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) | NCT05307939 | HPV Oropharynx Canc... HPV-Related Car... HPV-Related Mal... HPV Positive Or... | HPV ctDNA Assay MRI Studies EORTC QLQ H&N 3... MDADI-HN COST-FACIT Intensity-Modul... Chemoradiation ... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer | NCT02002182 | Head and Neck C... Squamous Cell C... HPV Positive Or... | ADXS11-001 (ADX... | 18 Years - | Baylor College of Medicine | |
| The SPOT-HPV Study | NCT05524025 | HPV Infection HPV Positive Or... | Salivary TTMV-H... Blood TTMV-HPV ... | 18 Years - | Dana-Farber Cancer Institute | |
| Interim Digital PET/CT in Predicting Outcomes for Participants With Locally Advanced Oropharyngeal Cancer Undergoing Chemoradiation Therapy | NCT03611205 | Oropharyngeal S... HPV Positive Or... | Computed Tomogr... Positron Emissi... | 18 Years - | Ohio State University Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
